Pluristyx provides the expertise and tools to support and accelerate the development and commercialization of revolutionary therapeutics to treat serious human diseases by providing unique products, expert consulting, and contract services.
Contract process development and manufacturing of cell based products
Ready-to-Differentiate® human Pluripotent Stem Cells and induced Pluripotent Stem Cells
Ready-to-Use™ differentiated PSC
Pluristyx to Support Development of Kiadis’ K-NK Cell COVID-19 Therapy Funded by $9.5 Million From the Advanced Regenerative Manufacturing Institute’s BioFabUSA Program
SEATTLE--(BUSINESS WIRE)-- Pluristyx, Inc., a leading chemistry, manufacturing, and controls (CMC), consulting, process development, and tools provider for cell and gene therapy companies, today announced it will be supporting a collaboration between Kiadis Pharma (Kiadis), and the Advanced Regenerative Manufacturing Institute’s (ARMI) BioFabUSA program working on Kiadis’ COVID-19 research and development program, Kiadis’ Natural Killer cells, (K-NK-ID101) as a universal countermeasure to fight COVID-19 and future pandemics.
AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications
ALAMEDA, Calif. & SEATTLE--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Pluristyx, Inc. (Seattle, WA), an advanced therapy tools and services company serving customers in the rapidly growing fields of regenerative medicine and cellular and gene therapies, today announced they have entered into a Manufacturing, Marketing, and Distribution Agreement through which Pluristyx will undertake these activities on behalf of AgeX with respect to AgeX’s research- and clinical-grade ESI brand human embryonic stem cells, sometimes referred to as hESCs.
Pluristyx announces strategic alliance with panCELLa and Implant Therapeutics of offer 'off-the-shelf' induced pluripotent stem cells.
Pluristyx, Inc., an advanced therapy tools and services biotechnology company, panCELLa, a privately held biotechnology company, and Implant Therapeutics, a developer of genetically-engineered stem cells, today announced they have entered into a manufacturing and distribution strategic alliance that offers cell therapy companies streamlined access to the next generation of safe, universal, cost-effective, “off-the-shelf” induced pluripotent stem cells (iPSCs). The agreement will enable commercial access to iPSCs containing panCELLa’s FailSafe™ and Implant’s hypoimmunogenic technology derived from fully-consented and regulatory appropriate donors. Both research and clinical grade panCELLa-owned iPSC lines will be manufactured and distributed by Pluristyx, who will also make custom iPSC lines incorporating panCELLa and Implant technology to meet unique customer needs.
Pluristyx and panCELLa Expand Intellectual Property Portfolio for Pluripotent Stem Cell Cloaking Technology
panCELLa granted patent in the United Kingdom for induced Allogeneic Cell Tolerance (iACT Stealth™) Technology
Pluristyx Featured in Labroots webinar
Dr. Ben Fryer, Co-Founder and CEO of Pluristyx, presented to webinar participants the “how and why” of integrating high quality ancillary raw materials into cell therapy product development and the manufacturing workflow, beginning with the starting cell source and MCB.
Pluristyx and Accelerated Biosciences announce availability of clinical-grade immune-privileged human trophoblast stem cells (hTSCs)
Pluristyx, Inc., an advanced therapy tools and services biotechnology company, and Accelerated Biosciences, a regenerative medicine innovator in the use of proprietary human trophoblast stem cells (hTSCs), today announced they signed an agreement for Pluristyx to manufacture clinical grade hTSC banks under Good Manufacturing Practices (GMP).